<DOC>
	<DOCNO>NCT00210769</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety tolerability maintenance effectiveness slow , extended-release oral formulation paliperidone administer daily patient diagnose schizophrenia .</brief_summary>
	<brief_title>A Study Long-term Safety Tolerability Long-term Effectiveness Extended-release Oral Paliperidone Patients Diagnosed With Schizophrenia</brief_title>
	<detailed_description>The controlled rate drug delivery provide extended-release oral formulation paliperidone may provide improved effectiveness reduce risk certain adverse effect patient schizophrenia , avoid peak troughs drug level blood . This could turn provide improve quality life overall functioning patient . This open-label study extension 6-week randomize , double-blind , parallel-group study effectiveness safety 4 different oral treatment administer daily compare patient schizophrenia : paliperidone 6 12 milligram ( mg ) , olanzapine 10 mg ( approve treatment schizophrenia ) , placebo . Following double-blind treatment phase , eligible patient may enter 52-week open-label extension slow , extended-release paliperidone ( comparison treatment ) . In open-label extension , patient , regardless randomize treatment double-blind phase , begin extended-release paliperidone 9 mg daily . Thereafter , patient maintain flexible dosage extended-release paliperidone throughout 52-week study . The dosage may increase decrease within range accordance clinical judgment investigator , base observation patient response tolerability . Because flexible dose closely mimic clinical practice , design may provide clinically relevant finding open-label setting.The final visit double-blind phase may serve initial visit open-label extension . Study visit occur Day 4 weekly first 4 week ( Weeks 1 , 2 , 3 , 4 ) every 4 week Week 52 early termination . Evaluations safety effectiveness extended-release paliperidone treatment perform schedule time throughout open-label extension . Flexible dosage ( 3 , 6 , 9 , 12 milligram ( mg ) ) extended-release paliperidone tablet administer orally daily 52 week , follow 6-week double-blind study patient receive fix oral dos 6 mg 12 mg extended-release paliperidone olanzapine 10 mg .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>As doubleblind study , diagnosis schizophrenia accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IV ) experience acute episode schizophrenia time screen doubleblind study , total PANSS score 70 120 complete doubleblind study discontinue least 21 day doubleblind treatment lack efficacy female patient childbearing potential , agreement continue use acceptable form contraception throughout openlabel extension , negative urine pregnancy test openlabel baseline . As doubleblind study , DSMIV axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen doubleblind study consider investigator significant risk suicidal violent behavior openlabel study receive injection depot antipsychotic since entry doubleblind study woman become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>extend release</keyword>
	<keyword>oral administration</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>dementia praecox</keyword>
	<keyword>mental disorder</keyword>
	<keyword>paliperidone</keyword>
	<keyword>PANSS</keyword>
</DOC>